Log in

Relevant bibliographies by topics / Cytochrome P-450 Genetic aspects

Academic literature on the topic 'Cytochrome P-450 Genetic aspects'

Author: Grafiati

Published: 4 June 2021

Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cytochrome P-450 Genetic aspects.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cytochrome P-450 Genetic aspects"

1

Setko, N. P., I. I. Berezin, T. V. Gorohova, A. G. Setko, and S. V. Movergoz. "Molecular-genetic and physiological aspects of workers’ adaptation to industrial environment factors." Sanitarnyj vrač (Sanitary Doctor), no. 9 (September 12, 2022): 673–79. http://dx.doi.org/10.33920/med-08-2209-06.

Full text

Abstract:

Molecular genetic studies of cytochrome P-450 genes and assessment of biological adaptation were carried out in 243 machinists and 202 sinkers employed in underground works. It is shown that the processes of adaptation to the factors of the production environment depend on the functionality of regulatory systems and on the characteristics of genetic associations. It was found that 15.3 % of machinists and 15.3 % of sinkers had a satisfactory level of adaptation, tension and an unsatisfactory level — 38.5 % of machinists and 84.6 % of sinkers; only 46.2 % of machinists failed to adapt. At the same time, up to 60 % of drifters had heterozygous mutations of the cytochrome P-450 genes, which provide effective adaptation to changing factors in the production environment, and up to 84.2 % of machinists had homozygous mutations.

APA, Harvard, Vancouver, ISO, and other styles

2

Roumak, V. S., N. V. Umnova, and G. A. Sofronov. "MOLECULAR AND CELLULAR ASPECTS OF DIOXIN TOXICITY." Annals of the Russian academy of medical sciences 69, no. 3-4 (August 21, 2015): 77–84. http://dx.doi.org/10.15690/vramn.v69.i3-4.1000.

Full text

Abstract:

Background: Using methods of molecular toxicology to study dioxin intoxication consequences the contribution was accessed of pathologic alterations induced and manifested by specific biomarkers and ecogenetic effects among Vietnamese population living on contaminated territories. The causes of variability in individual sensitivity to toxic activity were also evaluated. Materials and methods: Individual biomedical indices were compared between those living in contaminated with dioxins (n =8142) and control (n =4421) regions. Dioxin concentrations were measured by high resolution chromato-mass spectrometry (84 samples). The characteristics of cytochrome P-450 system state (94 persons) and cytogenetic parameters (368 persons, 331 450 cells) reflected the molecular and genetic effects. Variable sensitivity to dioxins was demonstrated by associations of genetic polymorphism (CYP1A1, GSTM1, GSTT1, n =195) and congenital morphogenetic variants among children (n =1734). Results: Numerous consequences were demonstrated among the exposed individuals: noticeable absobtion of dioxins from environmental objects; direct effects of P-450 system’s induction; systemic alterations in nucleus and genetic stability; changes in cellular generation’s rate. The associations were revealed of genetic polymorphism in xenobiotic biotransformation / detoxification system and the peculiarities of development and morphogenesis among exposed children. Conclusion: Characteristics of population chronicle intoxication with dioxins permitted to describe its numerous preclinical and clinical manifestations, to show the key elements in pathogenesis of revealed alterations. Future investigations are to create the groundwork for developing a method for prevention of dioxin pathology induction and realization based on revealing preclinical signs and effects of intoxication.

APA, Harvard, Vancouver, ISO, and other styles

3

Sychev, Dmitry A., Igor N. Sychev, Karin B. Mirzaev, Eric I. Rytkin, Dmitriy V. Ivashchenko, Irina V. Bure, and Vitaliy A. Otdelenov. "Clinical pharmacology technologies for personalization of cardiovascular diseases drug treatment: focus on direct oral anticoagulants." Annals of the Russian academy of medical sciences 74, no. 5 (December 4, 2019): 299–306. http://dx.doi.org/10.15690/vramn1214.

Full text

Abstract:

One of the main causes for adverse reactions development is not taking into account the pharmacokinetics of drugs and the dose. Pharmacokinetics of drugs is mostly defined by the cytochrome P-450 isoenzymes activity, carboxylesterases and many other isoenzymes of drug metabolism, as well as ADME transporters (P-gp etc.) which take part in the process of drug metabolism. The activity of these isoenzymes is defined by the genetic aspects of patients and non-genetic aspects such as comorbidity and drug-drug interactions. The development of complex algorithms for personalization of therapy based on the results of pharmacogenetic studies and in the form of a decision support system will play an important role in reduction of adverse drug reactions. A lot can be achieved for personalization of Direct Oral Anticoagulants for treatment of cardiovascular diseases. New approaches are being developed based on the results of pharmacogenetic and pharmacokinetic testing that will help diminish adverse effects of drugs.

APA, Harvard, Vancouver, ISO, and other styles

4

Resál, T., K. Farkas, and T. Molnár. "P546 The safety and efficacy of the new-generation budesonide-MMX in the aspect of the cytochrome P-450 enzyme genotype." Journal of Crohn's and Colitis 15, Supplement_1 (May 1, 2021): S516. http://dx.doi.org/10.1093/ecco-jcc/jjab076.667.

Full text

Abstract:

Abstract Background Unlike previous forms of budesonide absorbing from the ileal and ascending colon region, the new-generation budesonide-MMX contains a formula, that allows absorption throughout the whole colon. Budesonide is degraded in the liver by cytochrome P450 3A enzyme, but so far, there is no study examining the relationship between the budesonide’s effect and the enzyme activity. CYP3A5 is absent in 90% of the European/caucasian population due to a functional loss mutation (CYP3A5*3), whereas patients with the wild-type CYP3A5*1 allele may be expected to have increased metabolism. The most common genetic polymorphisms in CYP3A4 (CYP3A4*1B and CYP3A4*22) result in increased and decreased expression, respectively. Methods We enrolled 33 patients with UC in this prospective study until January of 2021. Patients received 9 mg oral budesonide-MMX once daily until 8 weeks. Laboratory parameters (cholesterol, triglyceride, CRP) and serum hormone levels (parathormone, dehydroepiandrosterone and cortisol) were monitored before and after the 8-week therapy to follow metabolic and hormonal changes. During these visits, body composition analysis was also performed with InBody 770 machine to observe the adverse effects of budesonide-MMX in respect of body fat mass, body mass index, protein content of the body and bone mineral content. We examined the CYP450 3A (CYP3A5 and CYP3A4) enzyme genotype of the patients, to see, whether the different alleles of this drug-degrading enzyme affect the efficacy and safety. Results 33 patients had received the 2-month therapy. By the end of follow-up, based on partial Mayo score, 26 (78.8%) patients experienced remission and 6 patients (18.2%) were primary non-responders. Mean pMayo score decreased from 4.18 to 1.63 (p<0.001). No significant changes were observable regarding body composition. Serum cholesterol level showed significant increase (p<0.001), while triglyceride and CRP did not show significant changes. Serum cortisol levels were decreased (p<0.001), while PTH and DHEA showed no significant decrease. Only two patients experienced side effects: one of them hypertonia, headache and acnes, while the other mild diarrhoea. 3 patients have CYP3A5*1/*3 genotype, and 16 have CYP3A5*3/*3. There was no significant difference between the two groups, regarding safety and efficacy. Only 1 patient have CYP3A4*1B genotype, while the rest have CYP3A4*1, hence, no statistics could be performed. Conclusion In our study, budesonide-MMX proved to be safe and effective in the therapy of UC, however, cholesterol was elevated in the serum. Based on our cohort, different genotypes of CYP3A don’t have an impact on the effect of the drug, however, CYP3A allele variants are rare, therefore, further examinations should be performed.

APA, Harvard, Vancouver, ISO, and other styles

5

Savelyeva, Marina I., Ekaterina O. Golubenko, Zhannet A. Sozaeva, Irina V. Poddubnaya, and Vera V. Korennaya. "Analysis of the complications of endocrine therapy with tamoxifen in breast cancer: clinical and pharmacogenetic aspects. Prospective pharmacogenetic cohort study." Journal of Modern Oncology 24, no. 3 (November 25, 2022): 361–67. http://dx.doi.org/10.26442/18151434.2022.3.201783.

Full text

Abstract:

Background. Tamoxifen is the drug of choice in ER-positive breast cancer (BC) therapy for perimenopausal women and one of the endocrine therapy options for menopausal patients. The pharmacological effect of tamoxifen can be influenced by the activity of cytochrome P450 (CYP) enzymes and P-glycoprotein transporters (Pg), and the genes encoding them have broad polymorphism, affecting serum concentrations of active metabolites. This article presents the overall results of a prospective population-based study of the clinical significance of genetic polymorphism of tamoxifen metabolic enzymes and transporters in breast cancer patients after radical treatment receiving adjuvant endocrine therapy with tamoxifen in outpatient settings during 2018-2019. The study was approved by the Research Ethics Committee of the Russian Medical Academy of Continuing Professional Education. Aim. To analyze the clinical presentation of endocrine therapy with tamoxifen in the adjuvant regimen and to assess the association of polymorphisms of genes encoding cytochrome P450 enzymes and drug transporter proteins with adverse events in BC patients. Materials and methods. One hundred and four women with stage I-III luminal breast cancer receiving adjuvant tamoxifen were examined for the presence of CYP2D6, CYP2C, and the following CYP3A gene polymorphisms: CYP2D6*4, CYP3A5*3, CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C19*3, as well as the ABCB1 gene polymorphic marker (C3435T) encoding the P-glycoprotein. The allelic variants were identified using the real-time polymerase chain reaction; the test was performed in the Research Center of the Russian Medical Academy of Continuing Professional Education. The study material was buccal epithelium (double sampling) taken after informed consent signing. Results. Association analysis showed the association of different genetic polymorphisms of CYP2D6, CYP3A5, CYP2C9, and ABCB1 with tamoxifen adverse drug reactions, indicating the clinical significance of these polymorphisms. Conclusion. With the implementation of genetic testing of the studied polymorphisms into the routine clinical practice of oncologists prescribing tamoxifen and gynecologists involved in the follow-up of breast cancer patients receiving endocrine therapy in the adjuvant mode, there will be an opportunity for more effective and safer pharmacotherapy.

APA, Harvard, Vancouver, ISO, and other styles

6

Mancilla-Morales, Misael D., Santiago Romero-Fernández, Araceli Contreras-Rodríguez, José J. Flores-Martínez, Víctor Sánchez-Cordero, L. Gerardo Herrera M., María F. López, and Enrico A. Ruiz. "Diverging Genetic Structure of Coexisting Populations of the Black Storm-Petrel and the Least Storm-Petrel in the Gulf of California." Tropical Conservation Science 13 (January 2020): 194008292094917. http://dx.doi.org/10.1177/1940082920949177.

Full text

Abstract:

Estimations on the influence of evolutionary and ecological forces as drivers of population gene diversity and genetic structure have been performed on a growing number of colonial seabirds, but many remain poorly studied. In particular, the population genetic structure of storm-petrels (Hydrobatidae) has been evaluated in only a few of the 24 recognized species. We assessed the genetic diversity and population structure of the Black Storm-Petrel ( Hydrobates melania) and the Least Storm-Petrel ( Hydrobates microsoma) in the Gulf of California. The two species were selected because they are pelagic seabirds with comparable ecological traits and breeding grounds. Recent threats such as introduced species of predators and human disturbance have resulted in a decline of many insular vertebrate populations in this region and affected many different aspects of their life histories (ranging from reproductive success to mate selection), with a concomitant loss of genetic diversity. To elucidate to what extent the population genetic structure occurs in H. melania and H. microsoma, we used 719 base pairs from the mitochondrial cytochrome oxidase c subunit I gene. The evaluation of their molecular diversity, genetic structure, and gene flow were performed through diversity indices, analyses of molecular and spatial variance, and isolation by distance (IBD) across sampling sites, respectively. The population genetic structure (via AMOVA and SAMOVA) and isolation by distance (pairwise p-distances and FST/1– FST (using ΦST) were inferred for H. microsoma. However, for H. melania evidence was inconclusive. We discuss explanations leading to divergent population genetic structure signatures in these species, and the consequences for their conservation.

APA, Harvard, Vancouver, ISO, and other styles

7

Setsune, J. I., and D. Dolphin. "Organometallic aspects of cytochrome P-450 metabolism." Canadian Journal of Chemistry 65, no. 3 (March 1, 1987): 459–67. http://dx.doi.org/10.1139/v87-080.

Full text

Abstract:

Carbeneiron porphyrins, (N,Fe)-bridged methyleneiron porphyrins, N-alkyliron porphyrins and σ-alkyliron porphyrins have all been shown to occur in nature and to be interconvertible via redox reactions. The chemistry of the naturally occurring iron porphyrins and model iron, cobalt, and ruthenium porphyrins is reviewed emphasizing their organometallic chemistry.

APA, Harvard, Vancouver, ISO, and other styles

8

Miles, J. S., A. W. Munro, B. N. Rospendowski, W. E. Smith, J. McKnight, and A. J. Thomson. "Domains of the catalytically self-sufficient cytochrome P-450 BM-3. Genetic construction, overexpression, purification and spectroscopic characterization." Biochemical Journal 288, no. 2 (December 1, 1992): 503–9. http://dx.doi.org/10.1042/bj2880503.

Full text

Abstract:

1. The gene CYP102 encoding cytochrome P-450 BM-3 and subgenes encoding the cytochrome P-450 and cytochrome P-450 reductase domains have been cloned in Escherichia coli. 2. The protein products of these genes have been overexpressed and purified to homogeneity. 3. The cytochrome P-450 domain is purified in the ferric low-spin state, but is readily converted into the high-spin state by addition of the substrate palmitate (Ks = 1 microM). The cytochrome P-450 reductase domain readily reduces cytochrome c. Mixing the two domains reconstitutes only about one-thousandth of the fatty acid hydroxylase activity associated with the intact cytochrome P-450 BM-3. 4. The X-band e.p.r. spectra of both the cytochrome P-450 domain and intact cytochrome P-450 BM-3 give g-values indicating low-spin ferric haem. The spectra are virtually identical with those of the equivalent form of cytochrome P-450 cam indicating that the haem ligation in cytochrome P-450 BM-3 is identical with that of cytochrome P-450 cam. 5. Resonance Raman spectra of the substrate-free and substrate-bound forms of the cytochrome P-450 domain are given. Spectral differences in comparison with cytochrome P-450 cam may reflect subtle electronic differences between the respective haem environments.

APA, Harvard, Vancouver, ISO, and other styles

9

Cusato, J., D. G. Ribaldone, L. Bertani, M. Antonucci, C. Tomasello, G. P. Caviglia, S. Dibetto, M. Mangia, M. Astegiano, and A. D’Avolio. "DOP20 Genetic of vitamin D as predictor of response to adalimumab in Crohn’s Disease." Journal of Crohn's and Colitis 15, Supplement_1 (May 1, 2021): S058—S061. http://dx.doi.org/10.1093/ecco-jcc/jjab073.059.

Full text

Abstract:

Abstract Background Personalised medicine is the direction towards are converging many efforts of experts in inflammatory bowel diseases (IBDs). The advent of biological drugs, with anti-TNF as first category, have revolutionized the managements of these patients. Unfortunately, several unmet needs are present, like an efficacy in about two third of the patients, onset of side effects like infections, paradoxical IMIDs. Being able to treat with these drugs only patients who will respond would avoid losing time without disease improvement and possible side effects. Vitamin D is important for several biological functions, such as regulation of the immune response and modulation of expression of genes encoding enzymes and transporters involved in drug metabolism and transport. Vitamin D is activated by cytochrome (CYP) 27B1, inactivated by CYP24A1, transported in kidney by Vitamin D binding protein (VDBP, encoded by GC gene) and carries out its activities through its receptor (VDR). No data are available concerning vitamin D genetics and response to anti-TNF drug adalimumab. The aim of this study was to describe the relationship between vitamin D pathway-related gene single nucleotide polymorphisms (SNPs) and adalimumab clinical outcome in a cohort of patients affected by Crohn’s disease. Methods We performed a multi-centre prospective study including patients affected by Crohn’s disease who started adalimumab therapy. SNPs in CYP27B1, CYP24A1, GC and VDR genes were analysed. Clinical outcome was considered as clinical response and remission at 3 months of therapy. Results We enrolled 69 patients. Median age was 40 (IQR 31–56) years, males were 40 (58%). Median basal calprotectin was 396 (IQR 188–851) mg/Kg, and 36 (53.7%) had a positive PCR value. We documented the following associations: CYP27B1 + 2838 CT/TT with perianal disease (p= 0.002), basal calprotectin (p= 0.018) and T3 calprotectin (p= 0.035), figure 1; CYP27B1-1260 GT/TT with perianal disease (p= 0.006), basal calprotectin (p= 0.036) and T3 calprotectin (p= 0.024); VDR ApaI CA/AA with basal calprotectin (p= 0.014) and T3 calprotectin (p= 0.036); VDR BsmI GA/AA with perianal disease (p= 0.036), and GC 1296 TG/GG with basal calprotectin (p= 0.014), figure 2. GC 1296 TG/GG genotype polymorphism (p= 0.044, figure 3) predicted clinical remission at multivariate analysis. Finally, median concentrations adalimumab trough levels at 3 months were 7.4 (IQR 5.5; 11.7) ug/mL. CYP24A1 3999 (p=0.025) and VDR TaqI (p=0.016) SNPs affected these levels. Conclusion This is the first study reporting the association between vitamin D pathway-related genetics and adalimumab treatment in a cohort of patients affected by IBD. Further studies in different and larger cohorts are needed to clarify these aspects.

APA, Harvard, Vancouver, ISO, and other styles

10

Abdalwahhab, Omir, Asmaa Galal-Khallaf, Samy Abd El-Latif Saber, Alaa GM Osman, and Khaled Mohammed-Geba. "A case study for application of DNA barcoding in identifying species and genetic diversity of fish from the Suez city market, Egypt." Aquatic Living Resources 33 (2020): 11. http://dx.doi.org/10.1051/alr/2020012.

Full text

Abstract:

The Red Sea is one of the key areas of biodiversity in the world. It is a hotspot for speciation and biological invasions. In the current work, a pilot, random sampling trial was carried out to characterize some species in the landings reaching the fish market in Suez city, which is one of the largest fish markets in the Northern Red Sea. Samples of different fish species were subjected to the standard procedures of DNA barcoding, applying the sequencing of the cytochrome oxidase subunit 1 mitochondrial gene (COI). DNA barcoding could successfully identify all the targeted fishes to the species-level (>98%). The results exhibited a taxonomically-versatile commercial trends in this market, being the collected species belonging to 7 different fish families and 3 orders. These species were Coris aygula, Papilloculiceps longiceps, Priacanthus sagittarious, Gerres longirostris, Alepes djedaba, Psettodes erumei Cheilinus trilobatus, Calotomus viridescens, and Pardachirus marmoratus. Haplotype diversities in the first six species were moderate. However, their nucleotide diversities were low. This may have resulted from fishing from bottlenecked populations, or from areas that do not hinder the genetic flow. Also, possible cryptic speciation could be detected in P. sagittarius, P. erumei and G. longirostris. Applying the DNA barcoding for species identification in Suez city fish market could then detect various aspects of fish species diversity. More works using the applied analyses can be strongly recommended to aid proper conservation and management of economic fisheries in the Red Sea.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Cytochrome P-450 Genetic aspects"

1

Hansen, Antony James. "Regulation of the expression of phenobarbital-inducible P450 genes." Title page, contents and summary only, 1989. http://web4.library.adelaide.edu.au/theses/09PH/09phh2491.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Elferink, Lisa Anne. "Characterization of the chicken phenobarbital inducible P450 gene family /." Title page, contents and introduction only, 1987. http://web4.library.adelaide.edu.au/theses/09PH/09phe39.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Gerber, Jaclyn. "Cytochrome P450 polymorphisms : relevance in two South African disease populations." Thesis, Stellenbosch : Stellenbosch University, 2003. http://hdl.handle.net/10019.1/53345.

Full text

Abstract:

Thesis (MSc)--Stellenbosch University, 2003.
ENGLISH ABSTRACT: With knowledge of the human genome increasing constantly we are continually faced with new and potentially groundbreaking methods for managing, treating and/or identifying diseases and predisposition to diseases and conditions at a genetic level. The human cytochrome P450 (CYP) super-family of genes code for enzymes that can participate in metabolism of drugs and foreign chemicals and in steroid synthesis and metabolism. Mutations in these genes may contribute to clinically relevant diseases. In this study, the effects of mutations within four CYP genes were evaluated in two South African disease groups - variegate porphyria and breast cancer. Variegate porphyria (VP) has an unusually high incidence in South Africa due to the R59W founder mutation in the protoporphyrinogen oxidase (PPOX) gene that causes a disruption in the haem biosynthetic pathway. VP presents with variable clinical symptoms and has a relatively low penetrance. It is expected that environmental factors and modifier genes play a role in the clinical expression of VP. CYP genes are implicated as candidate modifier genes for the expression of VP due to the function they have in metabolising many drugs contraindicated in porphyria patients, and the necessity of haem binding to the apoprotein to produce a functional CYP enzyme. This is the first study to investigate CYPs as possible modifier genes for VP clinical expression. Six CYP polymorphisms (CYPIAlml, CYPIAlm2, CYPIA2 - 734 C>A, CYPIBI 8372 A>C, CYP2D6*3, CYP2D6*4), associated with four CYP loci, were genotyped in a VP population and a suitable control population. The results observed are suggestive of CYPIAlml and CYPIBI playing a role as modifiers for the clinical expression of VP as they were significantly associated (PA and CYPIBI 8372 A>C). This represents the first investigation of the potential role of CYPs as breast cancer risk modifiers in the two South African populations. Significant differences were observed (PC polymorphism in the population of mixed ancestry. Vast differences in allele frequencies were also observed between the two groups of breast cancer populations. These results emphasize the importance of population-based risk assessment when genetic testing and counselling for complex disease susceptibility is offered. The results of this study provide the first evidence suggesting a role for CYPs in modifying the clinical expression of VP and in acting as risk factors for developing breast cancer in a South African population.
AFRIKAANSE OPSOMMING: Met die konstante toename van kennis oor die mensgenoom kom ons voortdurend te staan voor nuwe metodes vir die beheer, behandeling en/of identifikasie van siektes en vatbaarheid vir siektes op 'n genetiese vlak. Die mens sitochroom P450 geensuperfamilie kodeer vir ensieme betrokke in die metabolisme van medisyne en ander chemiese stowwe en steroïed-sintese en -metabolisme. Mutasies in hierdie gene kan 'n bydrae lewer tot kliniese relevante siektes. In hierdie studie is die effek van mutasies in vier sitochroom gene bestudeer in twee Suid-Afrikaanse siekte groepe, variegate porfirie en borskanker. Variegate porfirie (VP) het 'n besonderse hoë frekwensie in Suid-Afrika as gevolg van die R59W stigter-mutasie in die protoporfirinogeen oksidase (PPOX) geen. Hierdie mutasie lei tot 'n versteuring in die heem biosintese padweg. VP presenteer met variërende kliniese simptome en het 'n betreklike lae penetrasie. Daar word vermoed dat omgewingsfaktore en kandidaat modifiserende gene 'n rol speel in die kliniese beeld van VP. Sitochroom P450 gene is geïdentifiseer as kandidaat modifiserende gene as gevolg van hulle rol in die metabolisme van verbode medikasie vir porfirie pasiënte, asook die binding van heem aan die apoproteïen wat noodsaaklik is vir die produksie van funksionele sitochroom P450 ensiem. Hierdie is die eerste studie wat sitochroom P450 gene as moontlike modifiserende gene vir die kliniese uitdrukking van VP ondersoek. Ses sitochroom P450 polimorfismes (CYPIAlml, CYPIAlm2, CYPIA2 -734 C>A, CYPIBI 8372 A>C, CYP2D6*3, CYP2D6*4) is ondersoek in beide 'n VP populasie en 'n geskikte kontrole populasie. Die resultate suggereer 'n rol vir CYPIAlml en CYPIBI in die modifisering van die kliniese uitdrukking van VP aangesien hulle betekenisvolle assosiasie (PA, CYPIBI 8372 A>C). Hierdie studie verteenwordig die eerste ondersoek na die potensiële rol van sitochroom P450s as risiko-modifiserende faktore vir borskanker in die twee populasies. Betekenisvolle verskille (PC polimorfisme in die gemengde herkoms populasie. Beduidende verskille in alleel frekwensies is ook waargeneem tussen die twee borskanker populasies. Hierdie resultate beklemtoon die belangrikheid van populasie gebaseerde risiko-beraming wanneer genetiese toetse en voorligting vir komplekse siekte-vatbaarheid aangebied word. Die resultate van hierdie studie bied die eerste getuienis dat sitochroom P450s 'n rol kan speel in die modifisering van die kliniese beeld van VP en ook kan optree as as risiko faktore vir die ontwikkeling van borskanker in 'n Suid-Afrikaanse populasie.

APA, Harvard, Vancouver, ISO, and other styles

4

Wang, Jue. "Regulation and polymorphism of CYP2A6, CYP2B6 and CYP2E1 : functional and clinical aspects /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-650-6/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Truter, Erika. "Genetic association analysis of polymorphisms in four cytochrome P450 genes, the MDR1 gene and treatment-outcome in Xhosa schizophrenia patients." Thesis, Link to online version, 2007. http://hdl.handle.net/10019/350.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Gooden, Kyna McCullough Schroeder Jane C. "The relationship of uterine leiomyomata and genetic polymorphisms of Cytochrome P-450 1A1, Cytochrome P-450 1B1, and Catechol-O-Methyltransferase." Chapel Hill, N.C. : University of North Carolina at Chapel Hill, 2006. http://dc.lib.unc.edu/u?/etd,303.

Full text

Abstract:

Thesis (Ph. D.)--University of North Carolina at Chapel Hill, 2006.
Title from electronic title page (viewed Oct. 10, 2007). "... in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Epidemiology, School of Public Health." Discipline: Epidemiology; Department/School: Public Health.

APA, Harvard, Vancouver, ISO, and other styles

7

Hu, Yin. "Genetic polymorphism and regulation of cytochrome P450 2E1 /." Stockholm, 1999. http://diss.kib.ki.se/1999/91-628-3690-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

McLellan, Roman A. "Interindividual differences in xenobiotic-metabolising enzymes : the human genetic factor /." Stockholm, 2000. http://diss.kib.ki.se/2000/91-628-3924-1/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Oscarson, Mikael. "Genetic polymorphism of human drug metabolising enzymes : structural and functional studies /." Stockholm, 1999. http://diss.kib.ki.se/1999/91-628-3717-6/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Vadlamuri, Satya Vijayanand. "Genetic evaluation of cytochrome-P450 expression in smoking and nonsmoking women." Morgantown, W. Va. : [West Virginia University Libraries], 2001. http://etd.wvu.edu/templates/showETD.cfm?recnum=1806.

Full text

Abstract:

Thesis (Ph. D.)--West Virginia University, 2001.
Title from document title page. Document formatted into pages; contains xiv, 150 p. : ill. (some col.). Vita. Includes abstract. Includes bibliographical references (p. 104-120).

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Cytochrome P-450 Genetic aspects"

1

NATO Advanced Study Institute on Molecular Aspects of Drug Metabolizing Enzymes (1993 Kuşadası, Turkey). Molecular aspects of oxidative drug metabolizing enzymes: Their significance in environmental toxicology, chemical carcinogenesis, and health. Berlin: Springer-Verlag,in cooperation with NATO Scientific Affairs Division, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Klaus, Ruckpaul, and Rein Horst, eds. Molecular mechanisms of adrenal steroidogenesis and aspects of regulation and application. London: Taylor & Francis, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

NATO Advanced Study Institute on Molecular Aspects of Monooxygenases and Bioactivation of Toxic Compounds (1989 Çeşme, Turkey). Molecular aspects of monooxgenases and bioactivation of toxic compounds. New York: Plenum Press, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Schlezinger, Jennifer Joy. Involvement of Cytochrome P450 1A in the toxicity of aryl hydrocarbon receptor agonists: Alteration arachidonic acid metabolism and production of reactive oxygen species. Woods Hole, Mass: Massachusetts Institute of Technology, Woods Hole Oceanographic Institution, Joint Program in Oceanography/Applied Ocean Science and Engineering, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Klaus, Ruckpaul, and Rein Horst, eds. Basis and mechanisms of regulation of cytochrome P-450. London: Taylor & Francis, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ruckpaul, Klaus, and Horst Rein. Basis and Mechanisms of Regulation of Cytochrome P-450. de Gruyter GmbH, Walter, 2022.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Ruckpaul, Klaus, and Horst Rein. Molecular Mechanisms of Adrenal Steroidogenesis and Aspects of Regulation and Application. de Gruyter GmbH, Walter, 2022.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Costas, Ioannides, ed. Cytochromes P450: Metabolic and toxicological aspects. Boca Raton: CRC Press, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ioannides, Costas. Cytochromes P450: Metabolic and Toxicological Aspects. Taylor & Francis Group, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Cytochromes P450: Metabolic and Toxicological Aspects. CRC, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Cytochrome P-450 Genetic aspects"

1

Gillner, Mikael, Jan Bergman, and Jan-Åke Gustafsson. "Xenobiotic Regulation of Cytochrome P-450 Gene Expression." In Molecular Aspects of Monooxygenases and Bioactivation of Toxic Compounds, 283–92. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4684-7284-4_16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kalow, W. "Genetic Variation in the Hepatic Cytochrome P-450 System." In Human Genetics, 507–16. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71635-5_67.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Fujii-Kuriyama, Yoshiaki, and Osamu Gotoh. "Molecular Biology of Cytochrome P-450: Evolution, Structure and Regulation." In Molecular Aspects of Oxidative Drug Metabolizing Enzymes, 65–85. Berlin, Heidelberg: Springer Berlin Heidelberg, 1995. http://dx.doi.org/10.1007/978-3-642-79528-2_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Schenkman, John B., Kenneth E. Thummel, and Leonard V. Favreau. "Physiological and Pathophysiological Alterations in Rat Hepatic Cytochrome P-450+." In Molecular Aspects of Monooxygenases and Bioactivation of Toxic Compounds, 233–53. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4684-7284-4_13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Bossche, Hugo Vanden, Henri Moereels, and Paul A. J. Janssen. "Role of Cytochrome P - 450 in the Anabolism and Catabolism of Endobiotics." In Molecular Aspects of Monooxygenases and Bioactivation of Toxic Compounds, 305–30. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4684-7284-4_18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Gillette, James R., and Kenneth Korzekwa. "Overview: Theoretical Aspects of Isotope Effects on the Pattern of Metabolites Formed by Cytochrome P-450." In Advances in Experimental Medicine and Biology, 87–94. Boston, MA: Springer New York, 1991. http://dx.doi.org/10.1007/978-1-4684-5877-0_9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Philpot, Richard M., Rodolfo Gasser, and Michael P. Lawton. "Primary Structures and Regulation of Cytochrome P-450 Isozymes 2 (IIB) And 5 (IVB) and the Flavin-Containing Monooxygenase in Rabbit Liver and Lung." In Molecular Aspects of Monooxygenases and Bioactivation of Toxic Compounds, 55–73. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4684-7284-4_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Usanov, S. A., V. L. Chashchin, and A. A. Akhrem. "Chapter 1. Cytochrome P-450 Dependent Pathways of the Biosynthesis of Steroid Hormones." In Molecular mechanisms of adrenal steroidogenesis and aspects of regulation and application, 1–57. De Gruyter, 1990. http://dx.doi.org/10.1515/9783112563281-002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Takemori, S., and S. Kominami. "Chapter 5. Adrenal Microsomal Cytochrome P-450 Dependent Reactions in Steroidogenesis and Biochemical Properties of the Enzymes Involved therein." In Molecular mechanisms of adrenal steroidogenesis and aspects of regulation and application, 153–203. De Gruyter, 1990. http://dx.doi.org/10.1515/9783112563281-005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Morishima, Isao. "Pressure Effects on the Ligand-Binding Kinetics for Hemoproteins and Their Site-Directed Mutants." In High Pressure Effects in Molecular Biophysics and Enzymology. Oxford University Press, 1996. http://dx.doi.org/10.1093/oso/9780195097221.003.0016.

Full text

Abstract:

The effects of high pressure up to 1500 bar on the recombination kinetics of oxygen and carbon monoxide (CO) binding to human hemoglobin (intact and isolated chain forms), human myoglobin (and its mutants), and cytochrome P-450 were studied by the use of millisecond and nanosecond laser photolysis. The activation volumes for the binding of CO to the R- and T-quaternary states of hemoglobin (Hbs) were determined to be –9.0 and –31.7 ml, respectively. The characteristic pressure dependence of the activation volume was observed for the R-state Hb but not for the T-state Hb. More detailed studies were made with isolated α- and β-chains of human Hb. The kinetic data were analyzed on the basis of a simple three-species model, which assumes two elementary reaction processes of bond formation and steps of ligand migration. A pressure-dependent activation volume change from negative lo positive values in the bimolecular CO association reaction was observed for both chains. This is attributed to a change of the rate-limiting step from the bond-formation step to the ligandmigration step. High-pressure ligand-binding kinetics were also examined for site-specific mutants of human myoglobin in which some amino acid residues at the heme distal sites, such as Leu 29, Lys 45, Ala 66, and Thr 67, are substituted by others. The pressure dependence of the CO binding rate for the L29 mutants was unusual: a positive value was obtained unexpectedly for overall CO binding. Corresponding to this anomaly was an unusual geometry of the iron-bound CO, which was determined by IR and NMR spectroscopies. The effects of camphor and camphor analogues as substrates on the CO-binding kinetics for P-450cam were also studied under pressure. The positive activation volumes for CO binding were obtained for substrate-free and norcamphor- and adamantane-bound P-450, whereas other substrate analogue-bound P-450 complexes exhibited the negative activation volumes. All of the present high-pressure results are discussed in relation to (1) the dynamic aspects of the protein conformation, and (2) the specific participation of amino acid residues in the heme distal site in each elementary step of the ligand-binding reaction process.

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cytochrome P-450 Genetic aspects"

1

Dervisis, Nikolaos G., Maciej Parys, Annet Wenker, Patrick Venta, Barbara E. Kitchell, and Vilma Yuzbasiyan-Gurkan. "Abstract 2661: Evaluation of genetic variability of cytochrome P-450 members in the canine preclinical model." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2661.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!